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The multifunctional signaling protein p75 neurotrophin receptor (p75
NTR) is a central regulator and major contributor
to the highly invasive nature of malignant gliomas. Here, we show that neurotrophin-dependent regulated
intramembrane proteolysis (RIP) of p75
NTR is required for p75
NTR-mediated glioma invasion, and identify a previously
unnamed process for targeted glioma therapy. Expression of cleavage-resistant chimeras of p75
NTR or treatment of
animals bearing p75
NTR-positive intracranial tumors with clinically applicable c-secretase inhibitors resulted in
dramatically decreased glioma invasion and prolonged survival. Importantly, proteolytic processing of p75
NTR was
observed in p75
NTR-positive patient tumor specimens and brain tumor initiating cells. This work highlights the
importance of p75
NTR as a therapeutic target, suggesting that c-secretase inhibitors may have direct clinical application
for the treatment of malignant glioma.
Citation: Wang L, Rahn JJ, Lun X, Sun B, Kelly JJP, et al. (2008) Gamma-secretase represents a therapeutic target for the treatment of invasive glioma mediated by the p75
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Introduction
Human malignant glioma (MG) is one of the most common
primary central nervous system tumors in adults. These
tumors are diffuse, highly invasive, with dismal prognosis, and
long-term survivors are rare [1,2]. MG extend tendrils of
tumor several centimeters away from the main tumor mass.
These, as well as the recently identiﬁed brain tumor-derived
stem-like cells [3–6], herein called brain tumor-initiating cells
(BTICs), act as ‘‘disease reservoirs,’’ rendering these tumors
refractory to available treatments such as surgery or radio-
therapy [7,8]. The highly invasive nature of these tumors is the
result of genotypic and phenotypic changes that result in the
activation of a number of coordinate cellular programs,
including those necessary for migration (e.g., motility) and
invasion (e.g., extracellular matrix [ECM] degradation) [9] and
changes in pathway signaling that impart resistance to
conventional treatments by reducing proliferation and
increasing resistance to apoptosis [8,10,11]. A detailed
understanding of the mechanisms underlying this invasive
behavior is essential for the development of effective
therapies.
Several genes, including those that encode uPA/uPAR,
ephrinB3/EphB2, matrix metalloproteinases (MMPs), a dis-
integrin and metalloproteases (ADAMs), cathepsins, and
integrins, have previously been implicated in glioma invasion
[12]. More recently, gene expression proﬁling identiﬁed
several subclasses of gliomas that separate tumors into good
and poor prognosis groups of which diffuse inﬁltrative
gliomas are divided into four such subclasses [13]. One of
these four subclasses, designated hierarchical cluster 2B
(HC2B), was found to include several genes with speciﬁc
roles in cell migration and invasion, and membership in this
group was found to strongly correlate with poor patient
survival. Our understanding of the proteins that initiate, and
the pathways that regulate, glioma invasion is continually
expanding, such as the recent discovery that CD95 via the
activation of the PI3K/Akt/glycogen synthetase kinase
(GSK3b) pathway regulates glioma invasion [14]. However,
despite recent advances and efforts to target these speciﬁc
molecules or pathways, no clinically relevant agents have
been identiﬁed as yet. Using a discovery-based approach and
a series of functional, biochemical, and clinical studies, we
have identiﬁed the p75 neurotrophin receptor (p75
NTR)a sa
critical regulator of glioma invasion [15]. We found that
p75
NTR, through a neurotrophin-dependent mechanism,
dramatically enhanced migration and invasion of genetically
distinct glioma and that robust expression of p75
NTR was
detected in the highly invasive tumor cell population from
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NTR-positive glioblastoma patient specimens. In this
current study, we investigated the mechanism by which
p75
NTR imparts this highly invasive behavior to malignant
glioma, and assessed the use of a clinically applicable agent in
abrogating this invasive behavior.
p75
NTR elicits a large array of diverse biological responses
that are regulated by a complex layer of mechanisms. These
intricate layers of control have been proposed to explain the
variety of cellular effects triggered by p75
NTR activation. Key
p75
NTR signaling pathways already identiﬁed include Ras
homolog gene family, member A (RhoA), Jun N-terminal
kinase (JNK), mitogen-activated protein kinase (MAPK), and
nuclear factor j B (NFkB) [16]. These pathways are believed to
be activated by upstream proteins that directly associate with
various regions of the p75
NTR intracellular domain (ICD).
These proteins include guanine nucleotide dissociation
inhibitor (RhoGDI), ribosome-inactivating protein-2 (RIP-2),
and p75
NTR-associated cell death executor (NADE) [17–20],
which associate with a region referred to as the ‘‘death
domain’’; Schwann cell factor-1 (SC-1); neurotrophin recep-
tor-interacting MAGE homolog (NRAGE); tumor necrosis
factor (TNF) receptor-associated factor (TRAF), and neuro-
trophin receptor interacting factor (NRIF) [21–23], which
associate with the juxtamembrane region of p75
NTR; and a
PDZ-containing protein Fas-associated phosphatease-1 (FAP-
1), which associates with the C-terminal Ser-Pro-Val (SPV)
[24]. What proteins or biological process are activated by
p75
NTR, however, is highly cell context speciﬁc. In addition to
associating with other signaling molecules, p75
NTR, similar to
amyloid precursor protein (APP) and Notch, has been shown
to undergo regulated a-secretase and c-secretase cleavage,
referred to as regulated intramembrane proteolysis (RIP).
Cleavage of several type-1 transmembrane receptors has been
implicated and shown to be necessary in eliciting some
downstream biological responses [25–28]. a-Secretase cleav-
age of full-length p75
NTR by a sheddase liberates the
extracellular domain (ECD), leaving an unstable membrane-
bound C-terminal fragment (CTF) that is cleaved by the c-
secretase complex to release an ICD with potential signaling
capability [26,29]. Here, we show for the ﬁrst time to our
knowledge that regulated intramembrane proteolysis of
p75
NTR is a requirement for the highly invasive behavior of
p75
NTR-positive malignant glioma, and designate RIP as a
clinical target for the treatment of invasive malignant glioma.
Results
p75
NTR Proteolytic Processing Occurs in Patient
Specimens Endogenously Expressing p75
NTR
In a previous study, our laboratory identiﬁed p75
NTR as a
potent mediator of invasion in human glioma using a novel
invasive glioma mouse model generated by serial in vivo
selection [15]. In that study, we found that p75
NTR was
expressed in 22% mid-grade astrocytomas (two of nine) and
85% of glioblastoma multiforme (GBM) specimens (17 of 20),
and that the p75
NTR-positive glioma cells in the patient tumor
cell population were more migratory than the p75
NTR-
negative glioma cells. Here, we investigate the mechanism
underlying this p75
NTR-induced invasion. In neurons, p75
NTR
is a substrate for sequential a- and c-secretase–mediated
intramembrane proteolysis generating 24 kDa CTF and 19
kDa ICD fragments, respectively, and the generation of these
fragments are required for some of its biological functions
[26,28,30–34]. We therefore sought to determine whether
intramembrane proteolysis of p75
NTR occurred in malignant
glioma patient specimens. To do this, we assessed whether the
generation of the 24-kDa CTF and the 19-kDa ICD occurred
in a panel of surgically resected human glioma specimens and
normal human brain. Tumor and normal tissue taken at the
time of surgery were immediately snap frozen in liquid
nitrogen and stored at  80 8C. Frozen tumor tissue was
digested in lysis buffer and analyzed by western blots using a
p75
NTR cytoplasmic-speciﬁc antibody that not only detected
the full-length p75
NTR protein, but also detected p75
NTR-
positive fragments migrating at 24 and 19 kDa, respectively,
in the p75
NTR-positive specimens (eight of nine GBMs and
two of ﬁve Grade III glioma) (Figure 1A). Hence, p75
NTR
processing occurs in human glioma tumors, and this
suggested the possibility that p75
NTR processing is required
for glioma invasion.
p75
NTR Is Proteolytically Processed in Invasive Glioma Cells
To address the possible role(s) of p75
NTR proteolytic
processing in glioma cells, we assessed whether the appear-
ance of the p75
NTR-positive fragments at 24 and 19 kDa was
the result of proteolytic processing of the full-length p75
NTR
in invading glioma cells. We have previously established the
highly invasive glioma cell lines U87R and U251R for which
p75
NTR accounts for their invasive behavior [15]. The U87R
and U251R invasive glioma cells were grown in the absence or
presence of the proteasome inhibitor epoxomicin, a com-
pound used to inhibit rapid degradation of proteins often
associated with RIP-mediated proteins [26,35]. Western blot
analysis showed that in addition to the 75-kDa full-length
p75
NTR protein, 24-kDa and 19-kDa fragments (Figure 1B,
lane 1 and 5) were present and stabilized in the presence of 1
lM epoxomicin (Figure 1B, lane 2 and 6). These results are in
agreement with the model that the full-length p75
NTR protein
is cleaved, releasing the ECD, CTF, and intracellular frag-
ments. Next, we veriﬁed that the appearance of the 24-kDa
and 19-kDa fragments was the result of sequential cleavage of
p75
NTR by an a-secretase and then a c-secretase. First, we
determined whether treatment of p75
NTR glioma cells
(U87p75
NTR) using the TNF-a protease inhibitor (TAPI)-2,
known to inhibit metalloproteases and ADAMs such as tumor
necrosis factor-a converting enzyme (TACE) [36–38] and
previously shown to inhibit the proteolytic processing of
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Author Summary
Despite technical advances, clinical prognosis of patients with
malignant glioma, with an average survival of less than one year, has
not changed. The highly invasive nature of these tumors, together
with the recently identified brain tumor-initiating cells, provide
disease reservoirs that render these tumors incurable by conven-
tional therapies. Here, we present the first evidence to our
knowledge that regulated intramembrane proteolysis of the neuro-
trophin receptor p75
NTR is a critical regulator of glioma invasion.
Inhibition of this process by clinically relevant c-secretase inhibitors
dramatically impairs the highly invasive nature of genetically distinct
glioblastomas and brain tumor-initiating cells and prolongs survival.
These data highlight regulated intramembrane proteolysis as a
therapeutic target of malignant glioma and implicate the applica-
tion of c-secretase inhibitors in the treatment of these devastating
tumors.Figure 1. p75
NTR Is Proteolytically Processed in Patient Specimens and Invasive Glioma Cells
(A) Western blot analysis detected p75
NTR-positive fragments migrating at 24 and 19 kDa in patient specimens expressing p75
NTR (eight of nine GBMs,
two of five Grade III glioma) but was undetectable in tissue from normal human brain. U87 cells transfected with p75
NTR and grown in the presence of
the proteasome inhibitor epoxomicin (1 lM) were used as a positive control (C). Western blots probed for beta-actin were used as a loading control.
Molecular weight markers are indicated on the left.
(B) The highly invasive glioma cell lines U87R and U251R isolated by serial in vivo selection were treated with the proteasome inhibitor epoxomicin (Epo,
1 lM) and/or the c-secretase inhibitor, Compound X (CompX, 2 lM) for 4 h. Western blots for p75
NTR were probed with an antibody specific to the
cytoplasmic domain of p75
NTR which detects full-length (75 kDa), CTF (indicated by the less than symbol [,]; 25 kDa), and ICD (indicated by the asterisk
[*]; 19 kDa) peptides. The ICD is derived from the cleavage of the CTF, which is shown to visibly accumulate in the presence of a c-secretase inhibitor.
(C) p75
NTR proteolytic processing is a global event in human glioma cells. pcDNA3.1 encoding human p75
NTR or the empty pcDNA3.1 vector were stably
transfected into U87, U251, U118, and U343. Cells expressing p75
NTR (U87p75, U251p75, U118p75, and U343p75) were treated as described above.
Western blot analysis showed that all glioma cell lines tested cleaved the full-length p75
NTR to generate first the 24-kDa CTF and then the 19-kDa ICD.
doi:10.1371/journal.pbio.0060289.g001
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NTR in neurons [26,32,33,39], could inhibit p75
NTR
processing in glioma cells. TAPI-2 inhibited the proteolytic
processing of p75
NTR as indicated by the lack of CTF and ICD,
and abrogated p75
NTR-mediated invasion (Figure S1). Since
TAPI-2 has broad speciﬁcity, and glioblastomas are known to
produce high levels of many proteases, including members of
the MMP, ADAM, and ADAMTS families, leaving the exact
identity of the a-secretase unclear, we focused our efforts on
the second cleavage event. To determine whether the
generation of the 19-kDa fragment was the result of cleavage
of p75
NTR by a c-secretase, U87R and U251R cells were
treated with 2 lM Compound X (Calbiochem), a speciﬁc
inhibitor of c-secretase, for 4 h in the absence or presence of
epoxomicin. Western blot analysis of p75
NTR revealed that in
the presence of the c-secretase inhibitor, an accumulation of
the 24-kDa fragment occurred without subsequent cleavage
to the 19-kDa ICD, consistent with the release of the ICD of
p75
NTR by c-secretase (Figure 1B, lanes 3, 4, 7, and 8). The role
of processing of p75
NTR was not limited to a single glioma cell
line and was a general mechanism observed in glioma cells
established from genetically distinct individuals (U87p75,
U251p75, U343p75, and U118p75).We found that in all
p75
NTR-positive glioma cell lines, full-length p75
NTR was
cleaved to generate two fragments of 19 and 24 kDa: ICD and
CTF, respectively (Figure 1C). These results demonstrate that
regulated intramembrane proteolysis of p75
NTR is a global
event occurring in highly invasive p75
NTR-positive human
glioma cells.
c-Secretase Inhibition Significantly Abrogated p75
NTR-
Induced Glioma Migration and Invasion In Vitro
In neurons, ectodomain shedding of p75
NTR by a-secretase
and then c-secretase cleavage to generate an ICD fragment
can result in the activation of downstream events [26–28,30–
34]. To test whether the processing of p75
NTR resulting in the
release of the ICD fragment has a functional role in glioma
invasion, we analyzed in vitro migration and invasion of
U87R, U251R, U87p75
NTR, and U251p75
NTR glioma cell lines
using circular monolayer migration assays (Figure 2A and 2B)
and 3D-collagen invasion assays (Figure 2C and 2D) in the
absence and presence of the c-secretase inhibitor, Compound
X. p75
NTR-mediated glioma migration and invasion were
signiﬁcantly inhibited in the presence of Compound X. In
contrast, when the proteasome inhibitor epoxomicin was used
to stabilize p75
NTR-ICD, a signiﬁcant increase in migration
and invasion was seen (unpublished data), consistent with
increased invasion observed when a cDNA construct mimick-
ing the ICD fragment was ectopically expressed in U87 glioma
cells (Figure 3Aand 3B). To determine whether c-secretase
inhibition was conﬁned to glioma invasion or had effects on
other biological processes, we assessed the effect of c-
secretase inhibition on survival and proliferation of p75
NTR-
positive glioma cells. No signiﬁcant change was observed on
either survival or proliferation in vitro (Figure S2).
Biochemical Characterization of U87 and U251 Glioma
Cells Expressing p75
NTR Wild-Type or Cleavage-Resistant
Chimeric p75
NTR Alleles
It is well known that c-secretase has many substrates
[40,41]. To directly test the role of p75
NTR processing in
glioma invasion, we constructed cleavage-resistant chimeric
proteins of p75
NTR by replacing either the transmembrane
(p75FasTM) or the extracellular stalk domain of p75
NTR
(p75FasS) with equivalent domains from the Fas receptor [39]
(Figure 3C). Both p75
NTR and Fas receptors are members of
the TNF receptor superfamily, and although they each
contain similar domains, Fas, unlike p75
NTR,d o e sn o t
undergo RIP. Since ectopic expression of p75
NTR in the
human glioma cells lines U87 and U251 was sufﬁcient to
mediate glioma invasion [15], these cell lines were used as a
model system to assess the p75
NTR chimeric mutants. U87 and
U251 were therefore stably transfected with the cleavage-
resistant p75
NTR constructs (p75FasS and p75FasTM). To
ensure proper function of all p75
NTR protein constructs, we
assessed their location, topography, and ability to bind
neurotrophin in both U87 and U251 glioma cell lines.
Receptor orientation and localization at the plasma mem-
brane was conﬁrmed by ﬂow cytometric analysis using a
monoclonal antibody speciﬁc to the ECD domain of p75
NTR
(Figure S3A). As expected, all p75
NTR constructs were
expressed at the plasma membrane with the correct top-
ography. Next, we assessed whether the chimeric constructs
could still bind neurotrophin. Previously, we demonstrated
that in the absence of p75
NTR, glioma cells secrete high levels
of brain-derived neurotrophic factor (BDNF) protein into the
culture medium in vitro. When these same cells express
p75
NTR, the majority of the BDNF is found to be cell
associated, presumably bound to p75
NTR [15]. To conﬁrm
that the p75
NTR cleavage-resistant chimeric forms retained
the ability to bind neurotrophin, ELISA assays were
performed to detect BDNF expression in the conditioned
medium and total cell lysates of U87 and U251 cells
expressing p75FL, p75FasTM, p75FasS, and p75CRD130 (Fig-
ure S3B). p75CRD130 is a neurotrophin-binding mutant
created by inserting four amino acids after amino acid
residue 130 [15,42–47]. Expression of the chimeric p75
NTR
proteins (p75FasTM and p75FasS), just like the p75 wild type,
resulted in a shift in BDNF localization from the conditioned
medium to the cell lysate. This was in contrast to the cells
expressing the neurotrophin-binding mutant (p75CRD130)o r
the empty vector (pcDNA) where the bulk of BDNF was
detected in the culture medium. These data demonstrate that
p75
NTR cleavage-resistant chimeric constructs p75FasTM and
p75FasS retained their ability to bind neurotrophin (Figure
S3C). Once we conﬁrmed the correct expression and binding
of the various p75
NTR constructs, western blots using a
p75
NTR cytoplasmic domain-speciﬁc antibody were per-
formed to evaluate proteolytic processing of the various
p75
NTR receptors (Figure 3D). In cells expressing p75FasS,
only the full-length protein was detected, consistent with
inhibition of the a-secretase cleavage, whereas the full-length
75 kDa and the 24-kDa fragment were detected in cells
expressing the p75FasTM construct corresponding to the
ectodomain shedding of p75
NTR by a-secretase but with
inhibition of the c-secretase cleavage. Moreover, in the
presence of epoxomicin, no additional p75
NTR fragments
were observed (Figure S4). These results demonstrate the
cleavage-resistant chimeric p75
NTR alleles were expressed
with correct biochemical characteristics in U87 and U251
glioma cells. In addition, and consistent with the hypothesis
that proteolytic processing of p75
NTR is required for glioma
invasion, only the full-length 75 kDa band was detected in
lysates from U87 cells expressing p75CRD130, a p75
NTR
construct that was unable to induce glioma invasion [15].
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NTR Do Not
Induce Glioma Migration and Invasion In Vitro or In Vivo
Since we have shown that neurotrophin binding is required
for p75
NTR-mediated glioma invasion [15], and the neuro-
trophin-binding mutant p75CRD130 does not undergo RIP, it
would appear that RIP of p75
NTR is required for glioma
invasion. To determine whether this is in fact true, U87 and
U251 cells expressing the p75
NTR cleavage-resistant con-
structs were assessed for their invasive ability using 3D-
collegen invasion assays. We found that expression of
cleavage-resistant forms of p75
NTR (p75FasS, p75FasTM, and
p75CRD130), which prevented receptor proteolysis, blocked
p75
NTR-mediated glioma invasion (Figure 4A and 4B),
providing evidence to support a role for c-secretase–depend-
ent release of p75
NTR ICD in mediating glioma invasion.
To determine whether p75
NTR processing was required for
glioma invasion in vivo, U87 glioma cell lines ectopically
expressing p75FasS and p75FasTM were implanted into the
brains of immunocompromised (SCID) mice. U87 glioma cells
expressing full-length p75
NTR (U87p75) or control vector
(U87pcDNA) were used for comparison. Twenty-eight days
after implantation, the mice were sacriﬁced, and frozen brain
sections were stained with antibodies against human nuclei,
to visualize all glioma cells (Figure 4C, upper panel) or with
anti-human p75
NTR (Figure 4C, bottom panel). Implantation
of U87 glioma cells stably transfected with the control pcDNA
vector led to the formation of well-circumscribed tumors,
while U87 glioma cells ectopically expressing p75
NTR formed
tumors with highly inﬁltrative edges. In sharp contrast to the
p75
NTR-expressing U87 tumors, tumors expressing either
p75FasTM or p75FasS formed well-circumscribed tumors
similar to the p75
NTR-negative tumors (U87pcDNA). Com-
Figure 2. c-Secretase Inhibitor Significantly Inhibited p75
NTR-Induced Migration and Invasion in Glioma Cells
(A and B) Monolayer circular migration assays of U87R and U251R cells, which endogenously express p75
NTR, and U87p75 and U251p75 cells, which
ectopically express p75
NTR, were performed. Briefly, cells were seeded in monolayer wells through a cell sedimentation manifold. p75NTR-negative U87T,
U87pcDNA, U251T, and U251pcDNA cells were used for comparison. Once the sedimentation manifolds were removed, cells were given complete
medium containing 2 lM Compound X (CompX). Digital images of the cells were taken before migration at 0 h and then again at 72 h. Best-fit circles
were drawn around the area covered by the cells at the 0 h and 72 h time points, and the actual cell area was determined using Axiovision 4.2 imaging
software. Quantitative migration scores were calculated as the increase in the area covered by the cells beyond the initial area of the cells. c-Secretase
inhibitor Compound X significantly inhibited p75
NTR-induced migration. Values shown are the mean 6 s.e.m. from three independent experiments;
triple asterisks (   ) indicate p , 0.001 as compared to control (one-way analysis of variance [ANOVA] with the Neuman-Keuls post-test).
(C and D) 3D-collagen invasion assays of U87R, U87p75, U251R, and U251p75 cells were performed by mixing cells with 3D-collagen matrix (collagen,
fibronectin, and laminin) and then seeding them into 8.0-lm pore size transwell chambers in the presence or absence of 2 lM Compound X for 6 h.
Cells were fixed and stained, and invasive cells were counted. U87T, U87pcDNA, U251T, and U251pcDNA cells were used for comparison. Inhibition of c-
secretase by Compound X significantly inhibited p75
NTR-induced glioma invasion. Values shown are the mean 6 s.e.m. from three independent
experiments; triple asterisks (***) indicate p , 0.001 as compared to control (one-way ANOVA with the Neuman-Keuls post-test).
doi:10.1371/journal.pbio.0060289.g002
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In conjunction with the in vitro data, these data suggest that
proteolytic processing of p75
NTR is required for glioma
invasion in vivo (Figure 4C).
It is well known that the microenvironment of tumors can
change the biochemical characterization and function of
cells. We have demonstrated in vitro that glioma cells
expressing p75
NTR undergo proteolytic processing to gen-
erate ﬁrst the 24-kDa CTF and then the 19-kDa ICD. To
provide evidence that RIP of p75
NTR occurs in vivo, 7–9-lm
cryosections from mice implanted for 3–4 wk with in vivo–
selected U87R and U251R, or ectopically expressing p75
NTR,
p75FasS, p75FasTM, and pcDNA, were assessed for p75
NTR
processing by western blot. The 24- and 19-kDa fragments
were found in the highly invasive glioma cells, U87R, U251R,
and U87p75
NTR. In contrast, neither the 24-kDa nor the 19-
kDa fragment was seen in cells expressing p75FasS, and as
expected, only the 24-kDa fragment was detected in cells
expressing the p75FasTM, consistent with their in vitro
characterization (Figure 4D). These data further support a
role for RIP of p75
NTR in glioma invasion.
p75
NTR Proteolytic Processing Occurs in BTICs from Patient
Specimens That Endogenously Express p75
NTR
Our data demonstrated that 85% of GBM specimens (17/
20) express p75
NTR, that the p75
NTR-positive glioma cells in
Figure 3. Expression and Proteolytic Processing of p75
NTR Chimeric Alleles
(A) p75
NTR ICD is sufficient to induce invasion of U87 glioma cells in vitro. 3D-collagen invasion assays of U87p75ICD cells were performed by mixing
cells with 3D-collagen matrix (collagen, fibronectin, and laminin) and then seeding them into 8.0-lm pore size transwell chamber for 6 h. Cells were
fixed and stained, and invasive cells were counted. U87pcDNA and U87p75 cells were used for comparison. Values shown are the mean 6 s.e.m. from
three independent experiments; triple asterisks (***) indicate p , 0.001 as compared to U87pcDNA (one-way ANOVA with the Neuman-Keuls post-test).
(B) Western blot analysis detected a p75
NTR-positive fragment migrating at 19 KDa in U87 cells expressing the p75-ICD construct. U87p75
NTR glioma
cells treated with the proteasome inhibitor epoxomicin (Epo, 2 lM) were used as a positive control (U87-p75þEpo; the less than symbol [,] indicates
CTF; the asterisk [*] indicates ICD).
(C) Schematic diagram of the p75
NTR constructs. Chimeric proteins were created by replacing either the transmembrane (TM) or the extracellular stalk
(S) domain of p75
NTR with equivalent domains from the Fas receptor. The proteins were designated p75FasTM (FasTM) and p75FasS (FasS), respectively.
Other p75
NTR constructs were generated, including the neurotrophin-binding mutant in which the ligand-binding site was mutated by inserting four
amino acids after amino acid residue 130, designated p75CRD130 (CRD130), and the p75
NTR intracellular domain construct consisting of amino acids 238
to 399 (p75-ICD).
(D) Western blot analysis using a polyclonal p75
NTR antibody to the intracellular domain of p75
NTR confirmed the proper expression and processing of
all p75
NTR constructs (p75FL, p75FasTM, p75FasS,o rp75CRD130) in both U87 (left panel) and U251 (right panel) human glioma cell lines (the less than
symbol [,] indicates CTF; the asterisk [*] indicates ICD). To examine comparable levels of chimeric proteins, lysates were adjusted accordingly.
doi:10.1371/journal.pbio.0060289.g003
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migratory [15], and that 24- and 19-kDa p75
NTR-positive
fragments are present in p75
NTR-positive primary Grade III
and GBM patient specimens (Figure 1). We therefore wanted
to determine whether the appearance of these fragments in
the malignant glioma patient specimens was the result of
intramembrane proteolysis of p75
NTR.T od ot h i s ,w e
established primary cultures from human glioma patient
tumors. The recent discovery that human stem cell-like tumor
cells, termed BTICs, retain characteristics that closely
recapitulate the original patient tumor [3–6,48,49] prompted
us to establish the primary patient tumor cultures under
neural stem cell–promoting conditions. BTICs share charac-
teristics with neural stem cells (NSCs) such as continuous self-
renewal, extensive brain parenchymal migration and inﬁltra-
tion, and potential for full or partial differentiation, proper-
ties not found in established glioma cell lines [50,51].
Operative samples of human GBM were obtained at the time
of surgery, and brain tumor sphere cultures were established
in NS-A basal medium plus epidermal growth factor (EGF)
and basic ﬁbroblast growth factor (bFGF) (EF medium).
Immunocytochemical analysis of BTICs established from ﬁve
Figure 4. Cleavage-Resistant Chimeric p75
NTR Proteins Do Not Induce Migration and Invasion In Vitro or In Vivo
(A and B) The invasive ability of U87 (A) and U251 (B) stably transfected with p75
NTR or the p75
NTR cleavage-resistant chimeric constructs (p75FasS and
p75FasTM) were assessed using 3D-invasion assays. Expression of p75
NTR significantly increased invasion in the genetically distinct glioma cell lines U87
and U251, whereas neither p75FasS nor p75FasTM stimulated glioma invasion as compared to the p75
NTR-negative control cells (pcDNA). Values shown
are the mean 6 s.e.m. from three independent experiments; (the less than symbol [,] indicates CTF; the asterisk [*] indicates ICD; triple asterisks [   ]
indicate p , 0.001 vs. p75
NTR wild type, one-way ANOVA with Neuman-Keuls post-test).
(C) U87 cells stably expressing p75
NTR or the cleavage-resistant p75FasS and p75FasTM were implanted into the brains of SCID mice and allowed to
grow for 28 d. The mice were sacrificed, and frozen brain sections were stained with antibodies against human nuclei (top row, brown) and human
p75
NTR (bottom row, brown). Sections were counterstained with toluidine blue (blue). Scale bars in (C) represent 100 lm. Implantation of U87 glioma
cells stably transfected with the empty pcDNA vector or p75
NTR cleavage-resistant chimeras (p75FasTM and p75FasS), led to the formation of well-
circumscribed tumors. In marked contrast, animals implanted with U87 glioma cells ectopically expressing p75
NTR (U87p75) developed tumors with
highly infiltrative edges. Similar results were seen in three independent experiments with three animals in each group.
(D) p75
NTR cleavage-resistant chimeras do not generate ICD in vivo. Brain cryosections from SCID mice implanted with U87 glioma cells expressing
p75
NTR, p75FasTM,o rp75FasS were lysed in 23 loading buffer. Proteins were resolved on 10% SDS-PAGE gels and probed with a p75 cytoplasmic-
specific antibody. U87R, U251R, and U87p75, which express high levels of p75
NTR and exhibit increased invasive activity, process full-length p75
NTR to
generate both CTF and ICD in vivo. In contrast, and consistent with the in vitro data, the p75
NTR ICD peptide was not detected in tumors from animals
expressing p75FasS or p75FasTM. Cell lysates from U87 cells expressing p75
NTR and grown in the presence of epoxomicin (p75
NTRþEpo) or expressing
pcDNA (pcDNA) were used as positive and negative controls, respectively.
doi:10.1371/journal.pbio.0060289.g004
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proteins Nestin, Musashi, hSox2, and CD133 (J. J. P. Kelly, S.
Weiss, P. A. Forsyth, and D. L. Senger; unpublished data). In
addition, four out of ﬁve glioma tumor progenitor cells in
v i t r oe x p r e s s e dh i g hl e v e l so fp 7 5
NTR as detected by
immunocytochemistry (Figure 5A) and western blot (Figure
5B). To determine whether p75
NTR expressed on the BTICs
undergoes RIP, BTICs were grown in the absence and
presence of c-secretase and/or 2 lM epoxomicin. Similar to
the glioma cell lines, full-length p75
NTR, CTF, and ICD were
detected, and the 19-kDa ICD fragment was dependent on c-
secretase cleavage (Figure 5B). We next determined whether
the BTICs retained their expression of p75
NTR in vivo: BTIC
cells were implanted into the brains of SCID mice and
allowed to establish for 4–8 wk. Animals were sacriﬁced, and
frozen sections were stained with either an anti-human
nuclear antibody (to identify the human BTICs) or anti-
p75
NTR (Figure 5C). All tumors established from BTICs cells
showed highly inﬁltrative tumors, and consistent with the in
vitro data, four out of ﬁve tumors showed high expression of
p75
NTR in vivo.
c-Secretase Inhibitor Significantly Abrogated p75
NTR-
Induced Migration and Invasion In Vivo
p75
NTR as a substrate for c-secretase [26,33,39] adds to a
growing list of proteins shown to be substrates for c-secretase
cleavage, including APP [52–54], Notch [55,56], and Notch
ligands Delta1 and Jagged2 [57], ErbB4 [58], CD44 [59,60], and
E-cadherin [61,62]. Our in vitro data and the recent
application of c-secretase inhibitors (egs.LY-450139 and LY-
411575) in advanced clinical trials for Alzheimer disease [63–
65] prompted us to investigate the use of c-secretase
inhibitors to treat highly invasive gliomas. Using an intra-
cranial glioma model, we assessed the therapeutic potential of
c-secretase inhibitors. Parallel experiments were performed
using the genetically distinct U87p75
NTR and U251p75
NTR
glioma cell lines and the p75
NTR-positive BTICs established
from a patient GBM. Cells were implanted intracerebrally
Figure 5. Regulated Intramembrane Proteolysis Occurs in Brain Tumor-Derived Stem-Like Cells (BTICs) from Glioma Patient Specimens
(A and B) Primary cultures from human glioma patient tumor grown under brain tumor stem cell-promoting conditions (BTIC) express high levels of
p75
NTR (red) in vitro as detected by immunocytochemistry (A) and western blot (B). U87 cells stably expressing pcDNA and p75
NTR were used as
negative and positive controls, respectively. Cultures were counterstained with DAPI (blue) to visualize the cell nucleus. (B) p75
NTR expressed on the
BTICs undergoes RIP. BTICs were grown in the absence and presence of 2 lM c-secretase and/or 1 lM epoxomicin. Western blot analysis detected full-
length p75
NTR, CTF, and ICD with the accumulation of the 24-kDa CTF in the presence of the c-secretase inhibitor (CompX).
(C) Brain tumor-initiating cells (BTIC) express p75
NTR in vivo. BTIC cells were implanted into the brains of SCID mice and allowed to establish for 4–8 wk.
Animals were sacrificed, and frozen sections were stained with anti-p75
NTR (brown). Sections were counterstained with toluidine blue (blue). Tumors
established from BTICs express high levels of p75
NTR and form highly infiltrative tumors. M1 and M2 are individual mice.
doi:10.1371/journal.pbio.0060289.g005
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NTR Processing and Glioma InvasionFigure 6. c-Secretase Inhibitor Significantly Blocked p75
NTR Induced Glioma Migration and Invasion In Vivo
(A–C) u87p75
NTR (A), U251p75
NTR (B), or p75
NTR-positive BTICs established from a patient GBM specimen (C) were implanted intracerebrally into SCID
mice (m1–m3 and m7–m9 represent individual mice). Three days (U87p75
NTR and U251p75
NTR) or 5 d (BTIC) later, mice were administered s.c. 10 mg/kg
c-secretase inhibitor DAPT (c-SI) or vehicle (corn oil) alone, once/day for 2–3 wk (three to five mice/group). The mice were sacrificed, and frozen brain
sections were stained with an antibody against human p75
NTR (brown). Sections were counterstained with toluidine blue to visualize the cell nucleus
(blue). Control animals given vehicle alone (corn oil; middle row) developed tumors with highly infiltrative edges (top panels). In marked contrast,
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NTR
and U251p75
NTR or 5 d after for BTICs, mice were
administered subcutaneously (s.c.) either 10 mg/kg c-secretase
inhibitor or vehicle control (corn oil) once/day for 2–3 wk
(three to ﬁve mice/group). Tumors were allowed to grow for a
total of 4–6 wk, at which time, all animals were sacriﬁced,
their brains removed, frozen in O.C.T. compound, and
sectioned. Immunohistochemical staining of the frozen brain
sections for anti-human nuclei (unpublished data) or p75
NTR
(Figure 6A–6C) showed that animals implanted with
U87p75
NTR-, U251p75
NTR-, or p75
NTR-positive BTICs formed
tumors with highly inﬁltrative edges (Figure 6A–6C; upper
panels). In sharp contrast, animals implanted with
U87p75
NTR-, U251p75
NTR-, or p75
NTR-positive BTICs and
given the c-secretase inhibitor DAPT developed localized
tumors with highly demarcated edges (Figure 6A–6C; lower
panels). These results strongly suggested c-secretase inhib-
ition that results in blocking the generation of the p75
NTR
ICD substantially inhibited the invasive ability of glioma cells
in vivo. To establish whether the effects of the c-secretase
inhibition were conﬁned to glioma invasion or had con-
sequences on other biological functions, we assessed the
effect of c-secretase inhibition on glioma cell proliferation in
vivo and found no signiﬁcant change (Figure S5). The c-
secretase inhibitor had negliable effects on the self-renewal
capability of the BTIC line used in Figure 5 (unpublished
data).
To conﬁrm that administration of DAPT inhibited p75
NTR
ICD generation in vivo, 7–9 lm cryosections were lysed as
described previously, and western blots for p75
NTR were
performed (Figure 6D). These experiments show the presence
of full-length p75
NTR, CTF, and ICD in control animals that
received s.c. administration of vehicle (corn oil) alone. In
contrast, western blots of cryosections from animals that
received daily injections of the c-secretase inhibitor DAPT
detected only the full-length and CTF fragments of p75
NTR.
Subcutaneous administration of c-secretase inhibitor DAPT
inhibited the generation of the p75ICD and resulted in a
visible accumulation of the CTF. In addition and most
importantly, animals bearing U87p75
NTR orthotopic xeno-
graphs and given daily s.c. injections of the c-secretase
inhibitor DAPT survived signiﬁcantly longer (p , 0.0001)
than control animals (Figure 6E), further highlighting the
potential use of c-secretase inhibitors in the clinical treat-
ment of malignant glioma.
Discussion
The p75
NTR signaling cascade is a complex signaling axis
that depends on numerous factors, including cellular context
and speciﬁc protein interactions that inﬂuence biological
outcomes to regulated intramembranous proteolysis of
p75
NTR. For example, a recent report showed that in primary
cultures of cerebellar neurons, p75
NTR ectodomain shedding
and subsequent c-cleavage is necessary for the growth
inhibitory signal of myelin associated glycoprotein (MAG)
[33]. Conversely, in retinal ganglion cells, neurotrophin-
induced activation of p75
NTR was shown to promote neurite
growth in a RIP-dependent manner [66]. Ligand-dependent
induction of p75
NTR cleavage has also been reported in other
cell systems, including sympathetic neurons and glial cells
[28,30,34]. Similarly, we have shown that glioma migration is
neurotrophin dependent [15] and that this neurotrophin-
induced invasion is dependent on RIP of p75
NTR.
To assess the role of RIP in p75
NTR-mediated glioma
invasion, we used a pharmacological and molecular approach
both in vitro and in vivo to demonstrate that (1) p75
NTR
proteolytic processing occurs in glioma cell lines, surgically
resected tumor specimens, and BTICs isolated from patient
specimens; (2) cleavage-resistant alleles of p75
NTR are
insufﬁcient to mediate glioma invasion; and (3) pharmaco-
logical inhibition with a clinically applicable c-secretase
inhibitor results in a dramatic decrease of glioma invasion
both in vitro and in vivo and signiﬁcantly prolonged survival
of animals bearing p75
NTR-positive intracranial tumors.
Together, these data highlight the potential of using
pharmacological inhibition to interfere with RIP as a
therapeutic intervention for highly inﬁltrative p75
NTR-pos-
itive gliomas.
One of the initial steps in regulating RIP is the shedding of
the ECD by an a-secretase. This shedding event is required
for subsequent cleavage of the CTF to generate an ICD. In
order to show that both of these proteolytic events were
important in the processing of p75
NTR, we made a series of
chimeric molecules with the Fas receptor, a related family
member that does not generate CTF and ICD fragments
[39,67]. The means by which the ECD is shed from the full-
length p75
NTR protein and what its biological role is are not
fully understood [68–70]. Glioma cells are known to express
many proteases, including serine, cysteine, and metallopro-
teinases that are involved in invasion and tumor progression.
The ADAM metalloproteinase disintegrins, including
ADAM17 and ADAM10, have been described as prominent
sheddases for p75
NTR as well as other transmembrane type-1
receptors such as APP [71–73], with recent in vivo evidence
establishing a correlation with glioma invasion and an
increase in ADAM17 under hypoxic stress [74,75]. The use
of inhibitors targeting these proteinases may thus result in
preventing RIP of p75
NTR. Here, we have shown that the
broad-range metalloproteinase inhibitor TAPI-2 was able to
prevent both proteolytic processing of p75
NTR in glioma and
p75
NTR-mediated invasion. Although a possible therapeutic
animals that received daily injections of the c-secretase inhibitor DAPT (bottom panels) developed localized tumors with demarcated edges. Similar
results were seen in two independent experiments with three to five animals in each group.
(D) c-Secretase inhibitor blocks p75
NTR processing in vivo. Brain cryosections from three individual SCID mice implanted with u87p75
NTR-, U251p75
NTR-,
or p75
NTR-positive BTICs and administered s.c. 10 mg/kg c-secretase inhibitor DAPT or vehicle (corn oil) alone were lysed in 23loading buffer. Proteins
were resolved on 10% SDS-PAGE gels and probed with a p75 cytoplasmic-specific antibody. In animals given vehicle alone, western blot analysis
detected p75
NTR-positive fragments migrating at 75, 24, and 19 kDa, whereas in cryosections from animals given the c-secretase inhibitor DAPT, only
the full-length p75
NTR and 25-kDa CTF were detected. U87 cells expressing p75
NTR and grown in the presence of epoxomicin (control; C) were used as a
positive control. (The less than symbol [,] indicates CTF; the asterisk [*] indicates ICD.)
(E) c-Secretase inhibitor increases survival of animals bearing U87p75
NTR xenografts. Kaplan-Meier survival curves of SCID mice harboring U87p75
NTR
intracranial tumors given s.c. injections of 10 mg/kg c-secretase inhibitor DAPT or vehicle (corn oil) alone, once/day beginning on day 3. Animals given
the c-secretase inhibitor (GSI) survived significantly longer than control animals (p , 0.0001).
doi:10.1371/journal.pbio.0060289.g006
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NTR-positive tumors, previous
clinical attempts to inhibit the protease-rich environment of
tumors using broad-spectrum MMP inhibitors have so far
proven to be ineffective as anti-cancer agents, with phase II
and III trials failing to show efﬁcacy or survival beneﬁt
[76,77]. The reason for this lack of efﬁcacy may result in part
from the fact that glioblastomas produce high levels of
proteases, many of which have been suggested to help
facilitate tumor cell survival and invasiveness [74,78–83].
Attempts, therefore, to inhibit the ectodomain shedding of
p75
NTR in a clinical setting may prove difﬁcult.
The second proteolytic event with possible direct ther-
apeutic importance is mediated by the c-secretase complex,
which is composed of several proteins including presenilin,
nicastrin, APH-1, and presenilin enhancer 2 (PEN-2) [84].
This protein complex is known to be essential in the normal
processing of amyloid b-peptides from b-APP. Abnormal
accumulation of amyloid b-peptides with the formation of
plaques is believed to be the pathogenesis of Alzheimer
disease. Given the connection between Alzheimer disease and
c-secretase, there has been great interest in developing
compounds that can inhibit this protein complex with some
of these compounds already in phase II/III clinical trials [85].
The exact molecular mechanism(s) by which the ICD frag-
ment of p75
NTR exerts the invasive behavior of glioma cells is
unknown. As is the case with the Notch signaling pathway
[41,86,87], there have been recent studies to suggest that the
ICD fragment can translocate to the nucleus, but whether it
acts as part of a transcriptional complex is unclear [28,30]. In
addition, myelin-associated glycoprotein binding to cerebel-
lar neurons induces a- and c-secretase proteolytic cleavage of
p75
NTR, and the resulting ICD fragment is necessary for both
the activation of the small molecular weight GTPase, RhoA,
and inhibition of neurite outgrowth [33]. Whether these
processes or others are regulated by the p75
NTR ICD fragment
in glioma cells remains to be determined.
In our present study, we show that neurotrophin-induced
p75
NTR proteolytic processing is required for p75
NTR-medi-
ated glioma invasion in vitro and in vivo. Furthermore, daily
administration of the c-secretase inhibitor DAPT to animals
bearing p75
NTR-postive intracranial tumors signiﬁcantly
prolonged survival. These results are intriguing and support
the possible clinical application of c-secretase inhibitors for
the treatment of these deadly tumors. We cannot, however,
exclude the possibility that we are inhibiting the processing of
other proteins that may be involved in glioma invasion since
c-secretase is known to mediate the proteolytic processing of
several transmembrane proteins [52,53,55,57–61]. The bio-
chemical evidence presented here, however, supports the
hypothesis that the anti-invasive effect of c-secretase inhib-
ition is at least in part the result of inhibition of p75
NTR RIP.
Moreover, the fact that we did not observe any signiﬁcant
effects on proliferation or survival of the human glioma cells
in vivo suggests that the dominant mechanism of activity is
the inhibition of p75
NTR-mediated glioma invasion.
Excitingly, we also found that a large percentage (four out
of ﬁve) BTICs from primary glioma patient tissue express
high levels of p75
NTR. This rare population of cells with stem-
like properties and the ability to repopulate the tumor [3–6]
have been shown to be resistant to our current therapies
(radiation and temozolomide) and thus may represent a
‘‘disease reservoir’’ for these devastating tumors [88,89].
Unlike the U87 parental cells, these cells are highly invasive
in vivo, and treatment with a c-secretase inhibitor dramat-
ically blocked their invasive nature (Figure 6). Several recent
studies have demonstrated strong similarities between BTICs
and neural stem and progenitor cells [4,90,91]. However,
whether human glioblastoma stem cells arise from mutated
neural stem cells or a more mature cell type that acquires
self-renewal capacity remains to be determined. Interestingly,
a small population of cells (0.3%) within the stem cell niche of
the adult rat subventricular zone has neurosphere-forming
capacity, express p75
NTR [92], and appear to be maintained
from birth through adulthood [93–95]. In addition, the more
migratory p75
NTR glioma cell population in clinical glioblas-
toma patient specimens also represents a small percentage of
the main tumor mass [15]. It is intriguing to note that glioma
cells that express high levels of p75
NTR seem to possess many
characteristics of BTICs, including self-renewal, extensive
brain parenchymal migration, and potential for differentia-
tion (J. J. P. Kelly and S. Weiss, unpublished data). Whether
p75
NTR is an early brain tumor stem cell marker, at least for
some GBMs, remains to be determined.
In a previous study, we postulated that p75
NTR itself may be
a valid target for the treatment of glioma, and now we
propose that abrogation of the cellular processing of p75
NTR
represents an additional therapeutic target. Although these
inhibitors may have application in malignant glioma, they
may have an even broader application for cancer, as p75
NTR
has also been implicated in other cancers, including
melanoma, speciﬁcally the more aggressive melanomas that
metastasize to the brain [96–98]. Thereby, therapies that
target the processing of p75
NTR may also be beneﬁcial for
other metastatic cancers.
Materials and Methods
Cell culture. The human glioma cell lines U87, U118, and U343
were obtained from the American Type Culture Collection. The
human glioma cell line U251N was a kind gift from V. W. Yong
(University of Calgary, Calgary, Alberta, Canada). All cells were
maintained in complete media (Dulbecco’s modiﬁed eagle’s medium
[DMEM] F12 supplemented with 10% heat-inactivated fetal bovine
serum [FBS], 0.1 mM nonessential amino acids, 2 mM L-glutamine,
and 1 mM sodium pyruvate [Gibco BRL, http://www.invitrogen.com])
at 37 8C in a humidiﬁed 5% CO2 incubator. Cells were passaged by
harvesting with trypsin (Gibco BRL) at 80%–90% conﬂuence. Stable
transfectants of U87, U251, U118, and U343 cells were maintained in
identical media with the exception of the addition of 400 lg/ml of
G418 (Invitrogen, http://www.invitrogen.com).
Construction of p75
NTR cleavage-resistant plasmids. The human
p75
NTR expression vector was constructed as described previously
[98]. The expression plasmids containing the p75
NTR mutants were
constructed by subcloning of PCR fragments containing the desired
p75
NTR sequences. Chimeric proteins were created by replacing
either the transmembrane (p75FasTM) or the extracellular stalk
domain of p75
NTR (p75FasS) with equivalent domains from the Fas
receptor [Figure 3C] as described by Domeniconi et al. 2005 [33]. The
neurotrophin-binding mutant that was mutated by a four-amino acid
(ARRA) insertion after amino acid residue130 was termed
p75CRD130 [15,42,43,47]. The p75
NTR intracellular domain construct
was created using amino acids 236–399 of the wild-type receptor plus
a methionine at the amino terminus (p75-ICD). The original p75
NTR
templates were from B. Hempstead (p75WT; Weill Medical College of
Cornell University, New York, New York) and M. Chao (pT3/T7-p75;
New York University School of Medicine, New York, New York). All
constructs were inserted into pcDNA 3.1 expression vectors
(Invitrogen). The sequences of all the mutant expression plasmids
were conﬁrmed prior to stable transfection.
Transfection of glioma cell lines. Transfection of glioma cell lines
was performed as described previously [15]. Brieﬂy, cells to be
transfected were seeded at 2 3 10
5 cells/well in six-well plates, and
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using FuGENE 6 transfection reagent (Roche Diagnostic, http://www.
roche.com) according to the manufacturer’s instructions. The
following day, the medium was changed to fresh complete medium
containing the antibiotic G418 (concentration determined by toxicity
curve for each cell line) to select for those cells that had taken up the
vector. The cells were then grown under antibiotic selection until the
cells were at conﬂuence. For U87p75
NTR, U251p75
NTR, U118p75
NTR,
U343p75
NTR, U87p75FasTM, U87p75FasS, U87p75CRD130,
U251p75FasTM, and U251p75FasS transfection, transfected cells
were identiﬁed by ﬂow cytometry and western blot.
Western blotting. The desired cells were washed in ice-cold PBS
and lysed by gentle rocking in lysis buffer (50 mM Tris-HCl [pH 7.4],
150 mM NaCl, 10 mM NaF, 0.02% NaN3, 0.5% sodium deoxycholate,
0.1% SDS, 1% Nonidet P-40, 1% Triton X-100, 1 mM EDTA, 60 mM
b-octyl glucoside, 25 lg/ml aprotinin, 10 lg/ml leupeptin, 3 mM
sodium orthovanadate, 1 mM PMSF) at 4 8C. Cellular debris was
removed by centrifugation, and protein quantiﬁcation was per-
formed using the bicinchoninic acid (BCA) assay (Pierce Biotechnol-
ogy, http://www.piercenet.com). Proteins were resolved on 12% SDS-
PAGE gels, and western blots were performed using the following
primary antibodies: rabbit polyclonal anti-human p75
NTR intra-
cellular domain (Promega, http://www.promega.com), mouse mono-
clonal anti-human p75
NTR ECD (Upstate Biotechnology), mouse
monoclonal anti-b-tubulin (Sigma-Aldrich, http://www.sigmaaldrich.
com), or mouse monoclonal anti-b-actin (Cell Signaling Technology,
http://www.cellsignal.com). The appropriate HRP-conjugated secon-
dary antibody (Pierce Biotechnology) was used, and blots were
visualized using enhanced chemiluminescence (Amersham Bioscien-
ces).
Flow cytometric analysis of p75
NTR. A total of 1 3 10
6 cells stably
transfected with p75
NTR wild type or p75
NTR cleavage-resistant
constructs p75FasTM and p75FasS were collected using Puck’s EDTA
at 37 8C and then washed in PBS containing 1 mM EDTA (PBS/EDTA).
Cells were exposed to the monoclonal anti-p75
NTR, clone ME20.4
(which recognizes the extracellular domain; Upstate Biotechnology,
http://www.upstate.com), diluted 1:250 in PBS/EDTA for 30 min on
ice. Cells transfected with pcDNA vector alone were used as negative
controls. After washing with PBS/EDTA, cells were incubated with
Alexa-488 conjugated goat anti-mouse IgG (Invitrogen/Molecular
Probes, http://www.probes.invitrogen.com) diluted 1:500 in PBS/
EDTA for 30 min on ice. Cells were then washed with PBS/EDTA,
resuspended in PBS/EDTA, and analyzed using a FACScan ﬂow
cytometer (Becton, Dickinson and Company, http://www.
bdbiosciences.com).
ELISA. U87 and U251 glioma cells stably transfected with p75
NTR
wild type or the cleavage-resistant constructs were allowed to
condition culture medium for 5 d. The conditioned medium was
then collected, centrifuged, and ﬁltered through a 0.2-lm syringe
ﬁlter (VWR International, http://www.vwrcom). The remaining cells
were washed with ice-cold PBS, and total cellular lysates were
extracted as described for western blot. Protein quantiﬁcation was
performed using the BCA assay (Pierce Biotechnology), and BDNF,
nerve growth factor (NGF), or neurotrophic factor 3 (NT-3) ELISA
(R&D Systems, http://www.rndsystems.com) was performed as per the
company protocol. Brieﬂy, MaxiSorp ELISA plates (Nalge Nunc
International, http://www.nalgenunc.com.com) were coated with
monoclonal anti-human BDNF, NGF, or NT-3 (R&D Systems),
nonspeciﬁc binding was blocked, and then the standards of serial
dilutions of recombinant human BDNF, NGF, or NT-3 (Sigma-
Aldrich) and equal volumes of conditioned medium or equal
quantities of lysate were added. Bound antigen was detected using
the corresponding biotinylated antibody, streptavidin HRP, and a
tetramethylbenzidine substrate (R&D Systems). Absorbance was
measured at 450 nm.
In vitro p75
NTR proteolysis. For in vitro p75
NTR cleavage assess-
ment, the desired cells were treated for 4 h at 37 8C and 5% CO2 with
the proteasome inhibitor epoxomicin (1 lM) (Calbiochem, http://
www.emdbiosciences.com) and/or c-secretase inhibitor Compound X
(2 lM) (Calbiochem). DMSO was used as the vehicle control. Cells
were then washed one time with cold PBS on ice, lysed in lysis buffer
(50 mM Tris-HCl [pH 7.4], 150 mM NaCl, 10 mM NaF, 0.02% NaN3,
0.5% sodium deoxycholate, 0.1% SDS, 1% Nonidet P-40, 1% Triton
X-100, 1 mM EDTA, 60 mM b-octyl glucoside, 25 lg/ml aprotinin, 10
lg/ml leupeptin, 3 mM sodium orthovanadate, 1 mM PMSF) at 4 8C
with protease inhibitors, and centrifuged for 5 min at 14,0003g;
supernatants were quantiﬁed by BCA assay (Pierce Biotechnology) for
use in SDS-PAGE. The CTF (24 kDa) and ICD (19 kDa) fragments were
detected using an antibody speciﬁc to the p75
NTR ICD (Promega).
Circular Monolayer Migration Assay. Migration assays were
performed using a microliter-scale radial monolayer migration assay
as described previously [15]. Brieﬂy, ten-well Teﬂon-masked micro-
scope slides were coated with 20 lg/ml laminin, followed by the
addition of 50 ll of medium to each well. Sedimentation manifold
(Creative Scientiﬁc Methods, http://www.creative-sci.com) was placed
over the laminin-coated slide. Cells were seeded through the central
lumen of the cell sedimentation cylinder at 2,000 cells/well (ﬁve wells
per cell type/condition) to establish a circular 1-mm diameter
conﬂuent monolayer. Slides were placed on ice for 60 min and then
incubate at 37 8C for approximately 6 h. Attachment of the cells was
conﬁrmed prior to removing the sedimentation manifold. Once the
sedimentation manifolds were removed, cells were given complete
medium containing the c-secretase inhibitor (Compound X, 2 lM). A
digital image of the cells was taken (before migration ¼ 0 h) using a
Zeiss Axiovert 200M inverted ﬂuorescent microscope (Carl Zeiss,
http://www.zeiss.com). The cells were then incubated in a humidiﬁed
chamber at 37 8C and 5% CO2, and a second digital image was taken
48 h later. Best-ﬁt circles were drawn around the area covered by the
cells at the 0 h and 48 h time points, and the actual cell area was
determined using Axiovision 4.2 imaging software (Carl Zeiss).
Quantitative migration scores were calculated as the increase in the
area covered by the cells beyond the initial area of the cells.
3D-invasion assay. To test the invasive ability of the p75
NTR
cleavage-resistant constructs, actively growing glioma cells U87 and
U251 stably transfected with p75
NTR and p75
NTR cleavage-resistant
constructs were suspended in a collagen gel solution and plated in
transwell chambers with 8.0-lm pore size polycarbonate membrane
(Costar, http://www.costar.com). The collagen gel was prepared by
mixing collagen solution (Chemicon International 3D Collagen cell
culture system, Cat# ECM675, http://www.chemicon.com) with 53
DMEM F12 medium on ice. Neutralization solution (40:1) and
extracellular matrix (ECM) proteins were added at a concentration
of 10 lg/ml (laminin, ﬁbronectin, chondroitin sulfate proteoglycan,
Chemicon). A total of 1 3 10
5 cells were suspended in 350 llo f
collagen gel solution, and 70 ll of the collagen/cell mixture was
pipetted into the Transwell chambers (ﬁve chambers for each cell
line). Chambers were immediately transferred to a 37 8C incubator
for 60 min to allow the matrix to polymerize. Once polymerized, 100
ll of serum-free DMEM was added to the upper chamber and 1.0 ml
of 10% FBS complete medium with the c-secretase inhibitor
Compound X (2 lM) was added to the lower chamber. Transwell
chambers were kept at 37 8C for 6 h, at which time the chamber was
washed with PBS, ﬁxed with acid-alcohol for 15 min at room
temperature, and then stained with hematoxylin. Any cells remaining
in the top chamber were removed, and membranes were mounted on
glass slides. Four different ﬁelds were counted for each membrane.
Animals. Six- to 8-wk-old female SCID mice were purchased from
Charles River Laboratories (http://www.criver.com). The animals were
housed in groups of three to ﬁve and maintained on a 12-h light/dark
schedule with a temperature of 22 8C 6 1 8C and a relative humidity
of 50% 6 5%. Food and water were available ad libitum. All
procedures were reviewed and approved by the University of Calgary
Animal Care Committee.
In vivo studies using an intracranial glioma model. Actively
growing glioma cells stably transfected with p75
NTR and p75
NTR
cleavage resistant constructs were harvested by trypsinization,
washed, and resuspended in sterile PBS(137 mM NaCl, 8.1 mM
Na2HPO4, 2.68 mM KCl, and 1.47 mM KH2PO4 [pH 7.5]). These cells
were implanted intracerebrally into the right putamen of SCID mice
(1310
5 cells/mouse) at a depth of 3 mm through a scalp incision and
a 0.5-mm burr hole made 1.5–2 mm right of the midline and 0.5–1
mm posterior to the coronal suture. All mice were anaesthetized by
intraperitoneal administration of ketamine (85 mg/kg) plus xylazine
(15 mg/kg) (MTC Pharmaceuticals). The stereotactic injection used a
5-ll syringe (Hamilton Co., www.hamiltoncompany.com) with a 30-g
needle mounted on a Kopf stereotactic apparatus (Kopf Instruments).
After withdrawal of the needle, the incision was sutured. Animals
were sacriﬁced at speciﬁc time points (generally weekly, from 2–6 wk
postinjection) or when they lost 20% of their body weight or had
difﬁculty ambulating, feeding, or grooming. For some experiments,
BrdU was given by intraperitoneal injection 24 h prior to sacriﬁce.
Following sacriﬁce, the brains were removed, frozen in Tissue-Tek
O.C.T. compound (Electron Microscopy Sciences, http://www.
emsdiasum.com), and cryo-sectioned into 7–9-lm sections for
examination by immunohistochemistry and in vivo p75
NTR proteol-
ysis assessment.
Immunohistochemistry. Frozen sections were air-dried at room
temperature, ﬁxed with cold acetone, and then rinsed with PBS.
Endogenous peroxidases in the sections were inactivated with 0.075%
H2O2/methanol, and nonspeciﬁc binding was blocked with 10%
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polyclonal anti-human p75
NTR ICD antibody (Promega) or mouse
monoclonal anti-human nuclei (Chemicon) in blocking buffer over-
n i g h ta t48C. Following washing with PBS, the appropriate
biotinylated secondary antibody (Vector Laboratories, http://www.
vectorlabs.com) was applied. Avidin-biotin peroxidase complexes
were then formed using the VECTASTAIN Elite ABC kit (Vector
Laboratories) and detected by addition of SIGMAFAST DAB (3,39-
diaminobenzidine tetrahydrochloride) (Sigma-Aldrich), which was
converted to a brown reaction product by the peroxidase. Toluidine
blue (for frozen sections) was used as a nuclear counterstain. Sections
were then dehydrated in an ethanol/xylene series and mounted with
Entellan (Electron Microscopy Sciences).
In vivo p75
NTR proteolysis. For detection of p75
NTR proteolytic
processing in vivo, the desired cells were implanted intracerebrally
into SCID mice as described previously. Mice were sacriﬁced 3–4 wk
later. Following sacriﬁce, the brains were removed, frozen in Tissue-
Tek O.C.T. compound (Electron Microscopy Sciences), cryosectioned
into 7–9-lm sections, and alternating sections were stained with
toluidine blue. Based on the size of tumor, cryosections were lysed in
23 loading buffer (0.1 M Tris-HCl [pH 6.8], 4% SDS, 20% glycerol,
10% b-mercaptoethanol, 0.02% bromphenol blue). Proteins were
resolved on 12% SDS-PAGE gels, and western blots were performed
using an anti-p75
NTR cytoplasmic speciﬁc antibody (Promega).
Detection of p75
NTR proteolysis in patient specimens. Tumor and
normal tissues were obtained from the Canadian Brain Tumor Tissue
Bank in London, Ontario, and the Brain Tumor Tissue Bank at the
Clark Smith Brain Tumor Center within the Southern Alberta Cancer
Research Institute. Brieﬂy, tissue was taken during surgery while
patients were under a general anesthetic, and was placed immediately
in liquid nitrogen and stored at 80 8C. An institutional ethics board
approved the collection and use of all of the surgical tissue used, and
all of the patients gave signed informed consent. Frozen sections of
patient tumor tissue were lysed in lysis buffer (50 mM Tris-HCl [pH
7.4], 150 mM NaCl, 10 mM NaF, 0.02% NaN3,0 . 5 %s o d i u m
deoxycholate, 0.1% SDS, 1% Nonidet P-40, 1% Triton X-100, 1 mM
EDTA, 60 mM b-octyl glucoside, 25 lg/ml aprotinin, 10 lg/ml
leupeptin, 3 mM sodium orthovanadate, 1 mM PMSF) with protease
inhibitors on ice using a homogenizer (Life Technologies). Lysates
were centrifuged for 5 min at 14,0003g to remove debris, and
supernatants were quantiﬁed by BCA assay (Pierce Biotechnology). In
this study, based on our previous immunohistochemistry results of
p75
NTR expression in GBM patient specimens, western blot analysis
was performed on nine GBMs and ﬁve mid-grade glioma samples
using an antibody speciﬁc for the intracellular domain of p75
NTR.
Primary culture of brain tumor-initiating cells (BTICs). Tumor and
normal tissues were obtained from the Tumor Tissue Bank in
Foothills Hospital, Calgary, Alberta. Operative samples of human
gliomas were obtained during brain tumor surgery and transported
to the laboratory in serum-free DMEM-F12. Primary cultures of brain
tumor-initiating cells (BTICs) were established. Brieﬂy, necrotic and
connective tissue and any blood clots were removed using forceps,
and the remaining tissue was washed in PBS and cut into pieces of
approximately 1 mm
3. The tissue was then incubated for 5–10 min at
37 8C in an enzyme cocktail of trypsin (0.25%) and DNase I (10 lg/ml)
in PBS. The digested tissue was strained through a 100-lm mesh and
washed with PBS. Following lysis of the red blood cells, the remaining
cells were washed with PBS and strained through a 40-lm mesh. After
spinning at 1,000 rpm for 5 min, cells were resuspended in stem cell
medium (M medium) or stem cell medium plus EGF and bFGF (EF
medium). M medium is NeuroCult NS-A basal medium (human) 450
ml plus NeuroCult NS-A Proliferation Supplements (human) 50 ml
(StemCell Technologies). EF media is M media plus human
recombinant EGF (20 ng/ml; Sigma) and bFGF (20 ng/ml; Chemicon).
Immunocytochemistry of BTICs. Eight-well LAB-TEK chamber
slides (Nalgel Nunc, http://www.nuncbrand.com) were coated with
poly-L-ornithine (Sigma) and incubated at 37 8C for 1 h. The desired
BTICs were plated into chambers with stem cell culture medium to
equilibrate overnight at 37 8C, 5% CO2. Chambers were then rinsed
with PBS, ﬁxed in 3.7% paraformaldehyde diluted in PBS for 20 min,
and rinsed twice with PBS. Anti-p75
NTR cytoplasmic speciﬁc antibody
(1:3,000, Promega) and antibodies to the progenitor markers: Nestin
(1:1,000), hSOX2 (1:5,000), and mushashi (1:200) (R&D System) were
diluted in 0.3% Triton X-100/PBS/10% goat serum, and 200 llo f
these solutions were added to each chamber, incubated overnight at 4
8C. Following washing with PBS, the appropriate Cy-3– or FITC-
conjugated secondary antibodies (1:2,000) (Cedarlane, http://www.
cedarlanelabs.com) were applied and incubated for 30 min in the
dark at room temperature. The chambers were removed, and slides
were mounted with DAPI counterstained mounting medium (Vector
Laboratories) and imaged with an Olympus IX70 Delta Vision RT
microscope and the SoftWoRx software package.
Detection of p75
NTR proteolysis in BTICs. Based on the immuno-
cytochemistry staining results, BTICs were collected, dissociated by
polished glass pipette, aliquoted into six-well plates, and treated with
the proteasome inhibitor epoxomicin (1 lM) (Calbiochem) and/or the
c-secretase inhibitor Compound X (2 lM) (Calbiochem), or DMSO
vehicle alone, for 4 h at 37 8C and 5% CO2. Cells were then washed
twice with cold PBS on ice, lysed in lysis buffer with protease
inhibitors, and quantiﬁed by BCA assay. Western blots for p75
NTR
using a p75
NTR cytoplasmic-speciﬁc antibody were performed.
In vivo c-secretase studies using intracranial glioma models.
Actively growing glioma cell line U87p75 and BTICs were implanted
intracerebrally into SCID mice as described previously. Three days
later for the U87p75 cell line, and 5 d later for BTICs, mice were
administered s.c. vehicle (corn oil) or 10 mg/kg c-secretase in corn oil
once/day for 2 wk (U87p75
NTR) or for 3 wk (BTIC). At 3 wk for
animals bearing U87p75
NTR tumors or 4 wk for animals bearing BTIC
tumors, animals were sacriﬁced, the brains were removed, frozen in
Tissue-Tek O.C.T. compound, and cryosectioned into 7–9-lm
sections. The cryosections were used for tumor immunohistochem-
istry staining and for assessment of in vivo p75
NTR cleavage. For
survival studies (eight animals per group), U87p75
NTR glioma cells
were implanted intracerebrally into SCID mice. Animals were given
daily s.c. injections of 10 mg/kg c-secretase inhibitor DAPT or vehicle
(corn oil) alone, once/day beginning on day 3. Animals were followed
until sacriﬁce was required.
Statistical analysis. Statistical analysis of data was performed using
GraphPad Prism software (GraphPad Software). Survival curves were
generated using the Kaplan-Meier method. The log-rank test was used
to compare the distributions of survival times. A p-value of less than
0.05 was considered statistically signiﬁcant.
Supporting Information
Figure S1. TNF-a Protease Inhibitor (TAPI)-2 Prevents the Proteo-
lytic Processing of p75
NTR and Also Decreases the Migration of U87-
p75
NTR Cells
(A) A total of 7.5 3 10
5 U87p75 or U87pcDNA cells were plated in
collagen III-coated six-well plates and treated with either normal
growth medium or medium supplemented with TAPI-2 at 20 lM
overnight. Western blots for p75
NTR were probed with an antibody
speciﬁc to the cytoplasmic domain of p75
NTR, which detects full-
length (75 kDa), CTF (indicated by the less than symbol [,]; 25 kDa)
and ICD (indicated by an asterisk [*]; 19 kDa) peptides. In cell lysates
from U87p75 glioma cells, peptides corresponding to the full-length,
CTF, and ICD fragments were detected, whereas only the full-length
p75
NTR receptor was detected in cells treated with TAPI-2.
(B) A total of 5310
4 U87p75 or U87pcDNA cells were plated into the
upper chambers of Transwell plates coated with brain-like matrix
(collagen III with plasma ﬁbronectin, chondroitin sulfate proteogly-
cans, and laminins added as minor components). The cells were
treated with either normal growth medium, or medium supple-
mented with 20 lM TAPI-2 for 4 h. Cells were ﬁx/stained with 1%
crystal violet in ethanol, and the cells on the under side of the
membrane (migrated cells) were counted by light microscopy (n ¼ 7;
double asterisks [**] indicate p ¼ 0.019).
Found at doi:10.1371/journal.pbio.0060289.sg001 (258 KB PPT).
Figure S2. c-Secretase Inhibition Does Not Effect Proliferation or
Survival of p75
NTR-Expressing U87 Glioma Cells.
Inhibition of c-secretase does not effect proliferation or survival of
the highly invasive human glioma cell lines U87R isolated by serial in
vivo selection or the U87p75 cells, which ectopically express p75
NTR.
U87R and U87p75 were treated with and without 2 lM c-secretase
inhibitor Compound X (CompX), and survival and proliferation were
assessed at 72 h by MTT assay (A) and crystal violet proliferation assay
(B and C). The results show that 2 lM c-secretase inhibitor CompX
does not effect survival (A) or proliferation (B and C) of U87R and
U87p75 (p . 0.05).
Found at doi:10.1371/journal.pbio.0060289.sg002 (365 KB PPT).
Figure S3. Biochemical Characterization of U87 and U251 Glioma
Cells Expressing p75
NTR Wild Type or Cleavage-Resistant Chimeric
Alleles
(A) Expression and topography of the full-length, chimeric constructs
(p75FasTM and p75FasS) and the neurotrophin-binding mutant
p75CRD130 at the plasma membrane were conﬁrmed by ﬂow
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NTR extracellular domain-speciﬁc
antibody. U87pcDNA and U251pcDNA glioma cells were used as
controls.
(B–D) The p75
NTR cleavage-resistant constructs retain their ability to
bind ligand (C and D). Conditioned medium (B) and total cell lysates
(C) from U87 and U251 cells expressing full-length p75, p75FasTM,
p75FasS, and p75CRD130 were analyzed by ELISA for their ability to
bind BDNF. The p75
NTR-negative U87pcDNA and U251pcDNA were
used for comparison. Expression of p75
NTR full-length or the
cleavage-resistant chimeric proteins (p75FasTM and p75FasS) pro-
duced a shift in BDNF localization from the conditioned medium to
the cell lysate, consistent with the binding of BDNF to p75
NTR.I n
contrast, cells expressing the ligand-binding mutant p75CRD130 did
not produce a shift in BDNF localization in accordance with the in
ability to bind ligand. Values shown are the mean 6 standard error of
the mean (s.e.m.) for a single experiment. Similar results were seen in
three independent experiments; triple asterisks (   ) indicate p ,
0.001 as compared to pcDNA control for each cell line (one-way
ANOVA with the Neuman-Keuls post-test).
Found at doi:10.1371/journal.pbio.0060289.sg003 (442 KB PPT).
Figure S4. Proteolytic Processing of p75
NTR Mutant Chimeras
U87 (left panel) and U251 (right panel) stably transfected with p75
NTR
wild type, the cleavage-resistant chimeras (FasS and FasTM), or the
neurotrophin-binding mutant CRD130 were treated with the protea-
some inhibitor epoxomicin (Epo, 2 lM) and/or the speciﬁc inhibitor
of c-secretase, Compound X (CompX, 2 lM) for 4 h. Western blots for
p75
NTR were probed with an antibody speciﬁc to the cytoplasmic
domain of p75
NTR which detects full-length (75 kDa), CTF (indicated
by the less than symbol [,]; 25 kDa), and ICD (indicated by the
asterisk [*]; 19 kDa) peptides. In cell lysates from glioma cells
expressing p75FasTM chimera, only the 24-kDa fragment was
detected, whereas the p75FasS chimera and the p75CRD130 ligand
binding site mutant did not display any cleaved products.
Found at doi:10.1371/journal.pbio.0060289.sg004 (1.30 MB PPT).
Figure S5. c-Secretase Inhibition Does Not Effect Glioma Cell
Proliferation In Vivo
u87p75
NTR- (A), U251p75
NTR-, (B) or p75
NTR-positive BTICs estab-
lished from a patient GBM specimen (C) were implanted intra-
cerebrally into SCID mice. Three days (U87p75
NTR and U251p75
NTR)
or 5 d (BTIC) later, mice were administered s.c. 10 mg/kg c-secretase
inhibitor DAPT or vehicle (corn oil) alone, once/day for 2–3 wk (three
to ﬁve mice/group). Bromodeoxyuridine (BrdU) was injected into the
tumor-bearing mice 24 h prior to their sacriﬁce. Frozen brain
sections were stained with an antibody against BrdU and counter-
stained with toluidine blue to visualize the cell nucleus. Cells that had
divided during the 24 h prior to sacriﬁce stained positively for BrdU,
and the percentage of BrdU-positive cells were counted. Bar graph
represents the percentage of BrdU-positive cells in ﬁve consecutive
ﬁelds. The c-secretase inhibitor DAPT had no signiﬁcant effect on
proliferation in vivo of the p75
NTR-glioma cells as compared to their
untreated controls.
Found at doi:10.1371/journal.pbio.0060289.sg005 (60 KB PPT).
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